Clinical Trial Update: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Abemaciclib (LY2835219) plus Fulvestrant versus Placebo plus Fulvestrant in previously treated breast cancer has posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (Verzenio) (abemaciclib)
• Fulvestrant (Faslodex) (fulvestrant)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Breast Neoplasm, Neoplasm Metastasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-02-27